ACE-Breast-03 (ARX788, anti-HER2 ADC)
This is a Phase 2 study of ARX788 in subjects with advanced HER2 positive breast cancer who were previously treated with T-DM1, and/or T-DXd, and/or tucatinib-containing regimens in the metastatic setting.
We are recruiting patients in the U.S., Canada, Australia, Asia, Brazil, and Europe (Germany, Switzerland, UK, France, Italy, Portugal, Spain, Belgium, and Czech Republic).
For further information, please see: NCT04829604
Or email: email@example.com
About ARX788: The FDA granted ARX788 Fast-Track Designation for the treatment of HER2-positive metastatic breast cancer in December 2020. Updated ARX788 clinical data was presented as Spotlight Poster Discussion (PD8-04) at the 2021 San Antonio Breast Cancer Symposium (SABCS), in December 2021.